211 related articles for article (PubMed ID: 25072793)
1. Current state of practice regarding testosterone supplementation therapy in men with prostate cancer.
Kovac JR; Pan MM; Lipshultz LI; Lamb DJ
Steroids; 2014 Nov; 89():27-32. PubMed ID: 25072793
[TBL] [Abstract][Full Text] [Related]
2. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
Morgentaler A; Traish AM
Eur Urol; 2009 Feb; 55(2):310-20. PubMed ID: 18838208
[TBL] [Abstract][Full Text] [Related]
3. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
[TBL] [Abstract][Full Text] [Related]
4. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
6. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature.
Natale C; Carlos C; Hong J; Khera M; Baum N; Raheem OA
Sex Med Rev; 2021 Jul; 9(3):393-405. PubMed ID: 33516741
[TBL] [Abstract][Full Text] [Related]
7. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
Kaufman J
Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
[TBL] [Abstract][Full Text] [Related]
8. A new era of testosterone and prostate cancer: from physiology to clinical implications.
Khera M; Crawford D; Morales A; Salonia A; Morgentaler A
Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426
[TBL] [Abstract][Full Text] [Related]
9. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.
Guay AT; Perez JB; Fitaihi WA; Vereb M
Endocr Pract; 2000; 6(2):132-8. PubMed ID: 11421528
[TBL] [Abstract][Full Text] [Related]
10. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
11. Is testosterone a friend or a foe of the prostate?
Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
[TBL] [Abstract][Full Text] [Related]
12. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
Morales A
BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
[TBL] [Abstract][Full Text] [Related]
13. [Testosterone substitution therapy in prostate cancer].
Kaminsky A; Sperling H
Urologe A; 2011 Aug; 50(8):977-84. PubMed ID: 21811932
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
15. Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.
Neuzillet Y; Raynaud JP; Dreyfus JF; Radulescu C; Rouanne M; Schneider M; Krish S; Rouprêt M; Drouin SJ; Comperat E; Galiano M; Cathelineau X; Validire P; Molinié V; Fiet J; Giton F; Lebret T; Botto H
Horm Cancer; 2019 Feb; 10(1):36-44. PubMed ID: 30293206
[TBL] [Abstract][Full Text] [Related]
16. [Testosterone and the prostate].
Sperling H; Rossi R; Lümmen G; Rübben H
Urologe A; 2004 Sep; 43(9):1092-6. PubMed ID: 15368045
[TBL] [Abstract][Full Text] [Related]
17. The role of testosterone replacement therapy following radical prostatectomy.
Khera M; Lipshultz LI
Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
[TBL] [Abstract][Full Text] [Related]
18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
19. Testosterone deficiency syndrome: treatment and cancer risk.
Raynaud JP
J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):96-105. PubMed ID: 19429438
[TBL] [Abstract][Full Text] [Related]
20. Testosterone and prostate cancer: revisiting old paradigms.
Isbarn H; Pinthus JH; Marks LS; Montorsi F; Morales A; Morgentaler A; Schulman C
Eur Urol; 2009 Jul; 56(1):48-56. PubMed ID: 19375844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
